glp 1 for pediatrics Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Pediatric Obesity | Current Treatment Options in GLP-1 Medications in Pediatrics |

Pulmonologist Carol Ash, DO, explains how medications like the FDAapproved tirzepatide can support weight loss that reduces airway narrowing, lowers apnea events, and may make CPAP therapy easier to tolerate

This work was partially supported by National Natural Science Foundation of China 81872915 (M.-W.W.), 82073904 (M.-W.W.), 81922071 (Y.Z.), 81773792 (D.Y.), 81973373 (D.Y.) and 21704064 (Q.Z.)

FAQ 5: Should I stop taking my GLP-1 medication if Im experiencing hair loss

He has worked with GLP-1 medications and medical weight loss protocols for over a decade.

Truveta and collaborators partnered on a new large-scale study that considers the potential benefits of GLP-1 RA for AUD, among those with diabetes and/or obesity

The analysis included eight randomized controlled trials with 2,372 participants (all with BMI 27 kg/m) and found that weight regain was proportional to the amount initially lost.48 On average, participants who had taken liraglutide regained 2.2 kg, while those who had taken semaglutide or tirzepatide regained 9.69 kg after stopping the medication.48 Similarly, a 2025 review in Biomolecules showed that patients treated with GLP-1 or dual GLP-1/GIP agonists experience substantial weight loss (ranging from about 6% to over 20%) but also significant weight regain upon drug discontinuation